Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 16
2002 135
2003 153
2004 185
2005 218
2006 365
2007 346
2008 397
2009 347
2010 327
2011 297
2012 284
2013 316
2014 351
2015 317
2016 331
2017 321
2018 313
2019 304
2020 292
2021 269
2022 170
2023 129
2024 88

Text availability

Article attribute

Article type

Publication date

Search Results

5,726 results

Results by year

Filters applied: . Clear all
Page 1
JAK: Not Just Another Kinase.
Agashe RP, Lippman SM, Kurzrock R. Agashe RP, et al. Mol Cancer Ther. 2022 Dec 2;21(12):1757-1764. doi: 10.1158/1535-7163.MCT-22-0323. Mol Cancer Ther. 2022. PMID: 36252553 Free PMC article. Review.
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, Fujitani T, Honda T, Shibutani T, Muramatsu S, Nakada T, Goto R, Takahashi S, Yamaguchi M, Hamada H, Noguchi Y, Murakami M, Abe Y, Agatsuma T. Okajima D, et al. Mol Cancer Ther. 2021 Dec;20(12):2329-2340. doi: 10.1158/1535-7163.MCT-21-0206. Epub 2021 Aug 19. Mol Cancer Ther. 2021. PMID: 34413126 Free PMC article.
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
Cabaud O, Berger L, Crompot E, Adélaide J, Finetti P, Garnier S, Guille A, Carbuccia N, Farina A, Agavnian E, Chaffanet M, Gonçalves A, Charafe-Jauffret E, Mamessier E, Birnbaum D, Bertucci F, Lopez M. Cabaud O, et al. Mol Cancer Ther. 2022 Jul 5;21(7):1227-1235. doi: 10.1158/1535-7163.MCT-22-0013. Mol Cancer Ther. 2022. PMID: 35534238
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer.
Simoneau A, Engel JL, Bandi M, Lazarides K, Liu S, Meier SR, Choi AH, Zhang H, Shen B, Martires L, Gotur D, Pham TV, Li F, Gu L, Gong S, Zhang M, Wilker E, Pan X, Whittington DA, Throner S, Maxwell JP, Chen Y, Yu Y, Huang A, Andersen JN, Feng T. Simoneau A, et al. Mol Cancer Ther. 2023 Feb 1;22(2):215-226. doi: 10.1158/1535-7163.MCT-22-0409. Mol Cancer Ther. 2023. PMID: 36228090 Free PMC article.
Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P, Sun LL, Clark R, Hristopoulos M, Chiu CPC, Dillon M, Lin W, Lo AA, Chalsani S, Das Thakur M, Zimmerman Savill KM, Rougé L, Lupardus P, Piskol R, Husain B, Ellerman D, Shivva V, Leong SR, Ovacik M, Totpal K, Wu Y, Spiess C, Lee G, Leipold DD, Polson AG. Wang P, et al. Mol Cancer Ther. 2022 Jun 1;21(6):974-985. doi: 10.1158/1535-7163.MCT-21-0599. Mol Cancer Ther. 2022. PMID: 35364611 Free PMC article.
5,726 results